Immunome (NASDAQ:IMNM) Hits New 52-Week Low – Here’s What Happened

Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week low on Wednesday . The company traded as low as $8.30 and last traded at $8.46, with a volume of 23224 shares traded. The stock had previously closed at $8.36.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IMNM shares. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, March 10th. Lifesci Capital started coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $27.17.

Immunome Price Performance

The company’s 50-day simple moving average is $9.89 and its 200 day simple moving average is $11.66. The firm has a market cap of $678.26 million, a P/E ratio of -1.05 and a beta of 1.93.

Insider Activity at Immunome

In related news, CEO Clay B. Siegall acquired 150,000 shares of the stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 8.60% of the stock is owned by insiders.

Institutional Trading of Immunome

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its position in Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after buying an additional 13,757 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Enavate Sciences GP LLC bought a new stake in shares of Immunome in the 4th quarter worth about $36,939,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Immunome by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock worth $24,243,000 after acquiring an additional 246,447 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Immunome by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock worth $13,054,000 after purchasing an additional 21,396 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.